Liver cancer, more specifically hepatocellular carcinoma (HCC), is the second leading
cause of cancer-related death and its incidence is increasing globally. Around 50% of …

Immune checkpoint blockade (ICB) therapies have achieved clinical benefit, but most
'immune-cold'solid tumors are not responsive. The diversity of immune evasion mechanisms …

Tumour heterogeneity and a long-standing paucity of effective therapies other than
chemotherapy have contributed to triple-negative breast cancer (TNBC) being the subtype …

Tumor-infiltrating T cells offer a promising avenue for cancer treatment, yet their states
remain to be fully characterized. Here we present a single-cell atlas of T cells from 308,048 …

The accurate identification of antitumor T cell receptors (TCRs) represents a major challenge
for the engineering of cell-based cancer immunotherapies. By mapping 55 neoantigen …

B cells are frequently found in the margins of solid tumours as organized follicles in ectopic
lymphoid organs called tertiary lymphoid structures (TLS),. Although TLS have been found to …

Recent advances in cancer immunotherapy—ranging from immune-checkpoint blockade
therapy to adoptive cellular therapy and vaccines—have revolutionized cancer treatment …

Circulating tumour DNA (ctDNA) can be used to detect and profile residual tumour cells
persisting after curative intent therapy. The study of large patient cohorts incorporating …

Abstract Cyclin-dependent kinase 4 (CDK4) and CDK6 are critical mediators of cellular
transition into S phase and are important for the initiation, growth and survival of many …

Immune responses to cancer are highly variable, with mismatch repair-deficient (MMRd)
tumors exhibiting more anti-tumor immunity than mismatch repair-proficient (MMRp) tumors …